Suppr超能文献

构建并验证儿童哮喘初级预防的成本效益模型。

Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children.

机构信息

Department of General Practice, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, the Netherlands.

出版信息

BMC Med Res Methodol. 2011 Nov 9;11:150. doi: 10.1186/1471-2288-11-150.

Abstract

BACKGROUND

Given the rising number of asthma cases and the increasing costs of health care, prevention may be the best cure. Decisions regarding the implementation of prevention programmes in general and choosing between unifaceted and multifaceted strategies in particular are urgently needed. Existing trials on the primary prevention of asthma are, however, insufficient on their own to inform the decision of stakeholders regarding the cost-effectiveness of such prevention strategies. Decision analytic modelling synthesises available data for the cost-effectiveness evaluation of strategies in an explicit manner. Published reports on model development should provide the detail and transparency required to increase the acceptability of cost-effectiveness modelling. But, detail on the explicit steps and the involvement of experts in structuring a model is often unevenly reported. In this paper, we describe a procedure to structure and validate a model for the primary prevention of asthma in children.

METHODS

An expert panel was convened for round-table discussions to frame the cost-effectiveness research question and to select and structure a model. The model's structural validity, which indicates how well a model reflects the reality, was determined through descriptive and parallel validation. Descriptive validation was performed with the experts. Parallel validation qualitatively compared similarity between other published models with different decision problems.

RESULTS

The multidisciplinary input of experts helped to develop a decision-tree structure which compares the current situation with screening and prevention. The prevention was further divided between multifaceted and unifaceted approaches to analyse the differences. The clinical outcome was diagnosis of asthma. No similar model was found in the literature discussing the same decision problem. Structural validity in terms of descriptive validity was achieved with the experts and was supported by parallel validation.

CONCLUSIONS

A decision-tree model developed with experts in round-table discussions benefits from a systematic and transparent approach and the multidisciplinary contributions of the experts. Parallel validation provides a feasible alternative to validating novel models. The process of structuring and validating a model presented in this paper could be a useful guide to increase transparency, credibility, and acceptability of (future, novel) models when experts are involved.

摘要

背景

鉴于哮喘病例的增加和医疗保健成本的上升,预防可能是最好的治疗方法。目前迫切需要就一般预防计划的实施做出决策,并特别选择单一或多方面的策略。然而,现有的哮喘初级预防试验本身不足以告知利益相关者有关此类预防策略的成本效益的决策。决策分析模型以明确的方式综合了现有数据,以评估策略的成本效益。已发表的关于模型开发的报告应提供详细信息和透明度,以提高成本效益模型的可接受性。但是,关于明确步骤和专家在构建模型中的参与情况的详细信息往往报道得不均衡。在本文中,我们描述了一种用于构建和验证儿童哮喘初级预防模型的程序。

方法

召集专家小组进行圆桌讨论,以确定成本效益研究问题,并选择和构建模型。通过描述性和并行验证来确定模型的结构有效性,这表明模型在多大程度上反映了现实。描述性验证是由专家进行的。并行验证则定性比较了具有不同决策问题的其他已发表模型之间的相似性。

结果

专家的多学科投入有助于开发决策树结构,该结构将当前情况与筛选和预防进行了比较。预防进一步分为多方面和单一方法,以分析差异。临床结果是哮喘的诊断。在讨论相同决策问题的文献中没有发现类似的模型。通过专家达成了描述性有效性的结构有效性,并行验证也提供了支持。

结论

通过专家圆桌讨论开发的决策树模型受益于系统和透明的方法以及专家的多学科贡献。并行验证为验证新颖模型提供了可行的替代方案。本文介绍的构建和验证模型的过程可以作为专家参与时提高(未来的新型)模型透明度、可信度和可接受性的有用指南。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d83/3226537/ca9bdaf5665d/1471-2288-11-150-1.jpg

相似文献

1
Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children.
BMC Med Res Methodol. 2011 Nov 9;11:150. doi: 10.1186/1471-2288-11-150.
2
Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model.
Eur J Health Econ. 2014 Nov;15(8):869-83. doi: 10.1007/s10198-013-0532-x. Epub 2013 Oct 6.
3
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250.
5
Procedures and methods of benefit assessments for medicines in Germany.
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
6
How to develop cost-conscious guidelines.
Health Technol Assess. 2001;5(16):1-69. doi: 10.3310/hta5160.
7
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
8
Development of a conceptual model of childhood asthma to inform asthma prevention policies.
BMJ Open Respir Res. 2021 Nov;8(1). doi: 10.1136/bmjresp-2021-000881.
9
Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158. doi: 10.3310/hta8360.
10
A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening.
Appl Health Econ Health Policy. 2024 Jul;22(4):527-542. doi: 10.1007/s40258-024-00887-z. Epub 2024 May 16.

引用本文的文献

2
Developing a fall prevention intervention economic model.
PLoS One. 2023 Jan 27;18(1):e0280572. doi: 10.1371/journal.pone.0280572. eCollection 2023.
3
Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease.
PLoS One. 2022 Apr 28;17(4):e0267448. doi: 10.1371/journal.pone.0267448. eCollection 2022.
4
Development of a conceptual model of childhood asthma to inform asthma prevention policies.
BMJ Open Respir Res. 2021 Nov;8(1). doi: 10.1136/bmjresp-2021-000881.
5
Structuring a conceptual model for cost-effectiveness analysis of frailty interventions.
PLoS One. 2019 Sep 11;14(9):e0222049. doi: 10.1371/journal.pone.0222049. eCollection 2019.
7
Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model.
Eur J Health Econ. 2014 Nov;15(8):869-83. doi: 10.1007/s10198-013-0532-x. Epub 2013 Oct 6.

本文引用的文献

1
Empirically evaluating decision-analytic models.
Value Health. 2010 Aug;13(5):667-74. doi: 10.1111/j.1524-4733.2010.00698.x. Epub 2010 Mar 10.
4
Economic burden of asthma: a systematic review.
BMC Pulm Med. 2009 May 19;9:24. doi: 10.1186/1471-2466-9-24.
5
Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma.
Ann Allergy Asthma Immunol. 2008 Sep;101(3):316-24. doi: 10.1016/S1081-1206(10)60498-X.
10
The economic evaluation of prevention--let's talk about values and the case of discounting.
Int J Public Health. 2007;52(6):335-6. doi: 10.1007/s00038-007-0231-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验